CJC-1295 with DAC research and evidence overview

CJC-1295 with DAC is better documented than most research peptides — but the documentation is narrow. Two randomised, placebo-controlled trials in healthy adults established that it does what it was designed to do: raise growth hormone and IGF-1 for days at a time from a single injection. No published study has measured whether those hormone changes translate into altered body composition, strength, recovery, or any clinical endpoint, in any population, over any duration. The pharmacology is established; the benefit is not.

The foundational publication reports two randomised, double-blind, placebo-controlled trials in healthy subjects aged 21 to 61 (Teichman et al., Journal of Clinical Endocrinology & Metabolism 2006;91(3):799–805, PMID 16352683). The first used ascending single subcutaneous doses with 28 days of follow-up; the second used weekly or biweekly dosing over 49 days.

The measured effects:

• A single injection raised mean plasma GH concentrations 2- to 10-fold in a dose-dependent manner, sustained for 6 days or more.
• IGF-I rose 1.5- to 3-fold for 9 to 11 days.
• With repeated dosing, IGF-I remained elevated for up to 28 days.
• Estimated half-life: 5.8 to 8.1 days.
• No serious adverse reactions were reported; the compound was described as safe and relatively well tolerated within the parameters tested.

These are clean, specific, quotable numbers — which is precisely why this single paper carries almost the entire marketing case for the compound.

CJC-1295 is an analogue of growth hormone-releasing hormone. The Drug Affinity Complex is a chemical group that binds circulating albumin, which is what converts a peptide with a natural half-life measured in minutes into one with a half-life measured in days. The 5.8-to-8.1-day figure above is the direct evidence for that design working.

The same property is the source of the main open question. Native GHRH acts in pulses, and the pituitary responds to pulsatility; a compound that produces continuous, days-long stimulation is doing something physiologically different from what it mimics. Whether sustained elevation is preferable to pulsatile release for any given purpose is not answered by these trials.

The gap between the 2006 publication and the claims made for this peptide is the substance of this page:

• No trial reports body composition, lean mass, fat mass, or strength outcomes.
• No trial reports sleep, recovery, injury healing, or subjective wellbeing endpoints.
• Follow-up in the published studies runs to 49 days; there is no long-term safety data.
• No trial studied older adults, athletes, or people with growth hormone deficiency as a treatment population.
• The chronic-elevation questions that matter most for a GH-axis drug — insulin sensitivity, glucose tolerance, and tumour-risk surveillance over years — were outside these trials' scope.

Clinical development did not continue to an approved product. A 2026 narrative review of direct-to-patient peptides places CJC-1295 among compounds with scarce rigorous human safety and efficacy data (Mendias & Awan, Sports Medicine 2026, PMID 41966639).

CJC-1295 with DAC has no FDA-approved indication and is not a prescription medicine. Growth hormone secretagogues are prohibited in sport by the World Anti-Doping Agency.

The fair summary is that this compound has good phase 1 data and nothing else. "Raises IGF-1 for two weeks after one shot" is a demonstrated pharmacodynamic fact. "Therefore it builds muscle, burns fat, and improves recovery" is an inference no published study has tested, and the elevated-IGF-1 state that makes it appealing is the same state that generates its unanswered safety questions.